Valence 로고
인기
로그인
Loading data for SUPN — first visit, this takes a few seconds.

관심목록에 추가

Supernus Pharmaceuticals ...

NasdaqGM: SUPN · 실시간 가격 · USD
45.25
-0.60 (-1.31%)
종가 기준: Aug 24, 2026, 5:29 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

Supernus Pharmaceuticals Inc.(SUPN) 주가, 분석 및 데이터

-1.31%

데이터 없음

매수호가33.83
시가총액2.63B
매출 (ttm)830.44M
순이익 (ttm)-109.89M
0.56
-1.92
n/a
10.15
P/B (ttm)2.55
P/S (ttm)3.17
실적 발표일Nov 3, 2026
매도호가56
거래량246,083
평균 거래량 (20일)864,153
시가45.85
전일 종가45.85
일중 범위45.08 - 45.86
52주 범위42.45 - 59.68
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

SUPN 소개

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-r...

[더 보기]
산업 Drug Manufacturers - Specialty & Generic
섹터 Healthcare
IPO 일자 May 1, 2012
직원 수 778
상장 거래소 NasdaqGM
티커 SUPN
웹사이트 https://www.supernus.com
전체 기업 정보

재무 실적

2025년 Supernus Pharmaceuticals의 매출은 718.95M로, 전년 661.82M 대비 8.63% 증가했습니다. 순이익은 -38.55M로, -152.19% 감소했습니다.

재무제표

어닝 서프라이즈

Supernus Pharmaceuticals가 Aug 3, 2026에 분기 실적을 발표했습니다:
  • 매출 $219.06M 예상치 하회 $0, 및 32.40% 전년 대비 성장.
  • EPS 0.53 예상치 상회 0.02, 및 -41.76% 전년 대비 감소.

다음 실적 발표

Supernus Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 3, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드
news image

4일 전 · Zacks

Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

news image

4일 전 · Zacks

Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?

Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.

news image

5일 전 · Zacks

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

news image

1주 전 · StockStory

1 Healthcare Stock with Exciting Potential and 2 We Ignore

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only risi...

news image

1주 전 · StockStory

3 Russell 2000 Stocks We Approach with Caution

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the ...

2 페이지 중 1